Lisdexamfetamine

Drug Profile

Lisdexamfetamine

Alternative Names: Elvanse; Elvanse Adult; LDX; Lisdexamfetamine dimesilate; Lisdexamfetamine dimesylate; NRP-104; S-877489; SPD-489; Tyvense; Venvanse; Vyvanse

Latest Information Update: 05 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator New River Pharmaceuticals
  • Developer Lindner Center of HOPE; Shionogi; Shire
  • Class Amides; Amphetamines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder; Eating disorders
  • Phase II Mood disorders
  • Discontinued Bipolar depression; Cocaine abuse; Major depressive disorder; Schizophrenia; Sleep disorders

Most Recent Events

  • 18 Apr 2017 Launched for Attention-deficit hyperactivity disorder in USA (PO) (chewable tablet formulation)
  • 18 Apr 2017 Launched for Eating disorders in USA (PO) (chewable tablet formulation)
  • 10 Apr 2017 Shire terminates a phase III trial in Attention deficit hyperactivity disorders (In adolescents, In adults) in USA as the recruitment goals were not met (NCT01000064)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top